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To meet the challenge to human health posed by
obesity, a better understanding of the regulation of
feeding is essential. Medications targeting 5-hy-
droxytryptamine (5-HT; serotonin) 2C receptors
(htr2c; 5-HT2CR) improve obesity. Here we probed
the functional significance of 5-HT2CRs specifically
within the brainstem nucleus of the solitary tract
(5-HT2CR
NTS) in feeding behavior. Selective activa-
tion of 5-HT2CR
NTS decreased feeding and was suffi-
cient tomediate acute food intake reductions elicited
by the 5-HT2CR agonist obesity medication lorca-
serin. Similar to pro-opiomelanocortin neurons ex-
pressed within the hypothalamic arcuate nucleus
(POMCARC), a subset of POMCNTS neurons co-ex-
pressed 5-HT2CRs and were activated by 5-HT2CR
agonists. Knockdown of POMCNTS prevented the
acute appetite-suppressive effect of lorcaserin,
whereas POMCARC knockdown prevented the full
anorectic effect. These data identify 5-HT2CR
NTS as
a sufficient subpopulation of 5-HT2CRs in reducing
food intake when activated and reveal that 5-HT2CR
agonist obesity medications require POMC within
the NTS and ARC to reduce food intake.
INTRODUCTION
As demonstrated 40 years ago, brain 5-hydroxytryptamine
(5-HT; serotonin) is a significant regulator of appetite and body
weight (Breisch et al., 1976). Targeting this neurochemical
machinery, medications increasing 5-HT bioavailability were
developed to treat obesity. However, increasing 5-HT activity
at peripheral 5-HT receptors (5-HTRs) contributed to side effects
that led to the withdrawal of medications such as d-fenfluramine
in the 1990s and sibutramine in the 2000s (Burke and Heisler,
2015). Efforts to delineate 5-HTRs mediating 5-HT’s therapeutic
effects on food intake revealed the 2C receptor subtype (Htr2cr,
5-HT2CR) as the principal mediator (Tecott et al., 1995; Williams
et al., 2011). The clinical significance of this discovery is under-Cell Metabolism 28, 619–630, O
This is an open access article undscored by a new obesity medication, the 5-HT2CR agonist, lorca-
serin, which was recently launched in the United States (Aronne
et al., 2014; Smith et al., 2010).
5-HT2CRs are widely distributed within the brain where they act
to modulate a diverse array of behaviors and physiological pro-
cesses (Burke andHeisler, 2015; Julius et al., 1988). Of the neuro-
chemically defined cells expressing 5-HT2CRs, it is a subpopula-
tion of neurons within the arcuate nucleus of the hypothalamus
(ARC) that co-express the precursor polypeptide pro-opiomela-
nocortin (POMC) that have been proposed to be a principal medi-
ator of 5-HT2CR’s effects on metabolic functions (Berglund et al.,
2013;Burkeet al., 2017;Doslikova et al., 2013;Heisler et al., 2002;
Xu et al., 2010). However, anorectic doses of 5-HT2CR agonists
have been shown to increase markers of neuronal activity in
caudal brainstem regions, including the nucleus of the solitary
tract (NTS) (Lam et al., 2009; Stark et al., 2006). Although the
NTS is a brainstem structure known to be a key regulatory center
for the integration of food related signals of both peripheral and
central origin (Fan et al., 2004; Grill and Hayes, 2009; Zhan et al.,
2013), no direct functional assessment of 5-HT2CRs in this brain
regionhasbeenundertaken.Hereweprobed the functional signif-
icance of 5-HT2CRs within the NTS, their contribution to the ther-
apeutic effect of 5-HT2CR agonist obesity medications, and the
mechanismunderpinning their appetite-reducing effect via exclu-
sive action within the NTS.RESULTS
Selective 5-HT2CR
NTS Neuron Activation Decreases
Food Intake
To determine whether 5-HT2CR-expressing NTS (5-HT2CR
NTS)
neurons play a role in appetite control, we first employed the
chemogenetic designer receptors exclusively activated by
designer drugs (DREADDs; Armbruster et al., 2007) approach
to specifically express Gq-coupled (hM3Dq) or Gi-coupled
(hM4Di) designer receptors in 5-HT2CR
NTS neurons. To target
5-HT2CR
NTS neurons, we stereotactically delivered Cre-depen-
dent adeno-associated viruses (AAVs) encoding designer recep-
tor hM3Dq or hM4Di into the NTS of 5-HT2CR
Cre mice (Burke
et al., 2016, 2017; Marcinkiewcz et al., 2016) to generate
5-HT2CR
NTS-hM3Dq (Figures 1A and 1B) and 5-HT2CR
NTS-
hM4Di cohorts (Figures S1A and S1B). Cre recombinase activityctober 2, 2018 ª 2018 The Authors. Published by Elsevier Inc. 619
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Activation of 5-HT2CR
NTS-Ex-
pressing Neurons Reduces Food Intake
(A) Schematic of the strategy used to selectively
activate 5-HT2CR
NTS neurons; stereotactic injec-
tion of Cre-dependent DREADD vectors into NTS
of 5-HT2CR
Cre mice.
(B) 5-HT2CR
Cre construct and Cre-mediated
recombination of DREADD allele.
(C) Expression of the DREADD-fused mCherry
reporter protein within the NTS using immuno-
histochemistry for mCherry (mCherry-IR; red).
In vivo, CNO (1 mg/kg, intraperitoneally [i.p.])
increased FOS-IR (green) expression in the ma-
jority of 5-HT2CR
NTS-hM3Dq-expressing neurons
(red, bottom panels), whereas saline treatment did
not (top panels).
(D) Ex vivo, bath application of CNO (10 mM)
increased the firing frequency of 5-HT2CR
NTS-
hM3Dq-expressing neurons.
(E) CNO (1 mg/kg, i.p.) elicited a significant
reduction in ad libitum dark cycle food intake
compared with saline treatment in 5-HT2CR
NTS-
hM3Dq mice (n = 6–7; 3 hr: t12 = 3.57, p = 0.004;
5 hr: t12 = 3.379, p = 0.005; 24 hr: t12 = 1.876,
p = 0.0874). Data are presented as mean ± SEM.
**p < 0.01.
NTS, nucleus of the solitary tract; AP, area post-
rema; CC, central canal. Scale bar, 200 mm. See
also Figure S1.in 5-HT2CR
Cre mice efficiently recombined the DREADD-
mCherry allele in the NTS, as seen by the expression of the
mCherry reporter protein in transduced cells (Figure 1C). A de-
gree of spread was observed in adjacent regions following
amplification of mCherry signal with immunohistochemistry (Fig-
ure 1C). Following treatment with designer drug clozapine-N-
oxide (CNO; 1 mg/kg, intraperitoneally [i.p.]), c-fos immunoreac-
tivity (FOS-IR; a surrogate marker of neuronal activation)
was observed within the NTS of 5-HT2CR
NTS-hM3Dq mice. In
5-HT2CR
NTS-hM3Dq mice that had been fasted overnight to
decrease baseline FOS-IR, quantification analysis revealed
that approximately 76.4% ± 3.7% of mCherry-positive NTS cells
expressed FOS-IR following CNO treatment whereas less than
1% expressed FOS-IR following saline treatment (Figure 1C).
Consistent with these in vivo data, in ex vivo NTS slices, bath
application of CNO (10 mM) increased the firing frequency of
5-HT2CR
NTS-hM3Dq-expressing neurons (n = 5/5; Figure 1D).
These data indicate that CNO allows remote chemical control
of 5-HT2CR
NTS neuronal activity in 5-HT2CR
NTS-hM3Dq-express-
ing mice. We next examined the effect of CNO on feeding
behavior. CNO (1 mg/kg, i.p.) significantly reduced the first 5 hr
of ad libitum dark cycle chow intake compared with saline treat-
ment in 5-HT2CR
NTS-hM3Dq mice (Figure 1E).
Despite the CNO (10 mM)-induced reduction in membrane
potential observed in ex vivo NTS slices from 5-HT2CR
NTS-620 Cell Metabolism 28, 619–630, October 2, 2018hM4Di mice (n = 5/5; Figure S1C), CNO
(1 mg/kg, i.p.) did not affect ad libitum
food intake in 5-HT2CR
NTS-hM4Di
mice compared with saline (Fig-
ure S1D). The effect of CNO on feeding
behavior in 5-HT2CR
NTS-hM3Dq but not5-HT2CR
NTS-hM4Di mice illustrates that CNO is not altering
food intake via action at endogenous receptors. Rather, the
designer drug CNO is reducing food intake via action at the
designer 5-HT2CR
NTS-hM3Dq receptors. These data reveal that
activation of 5-HT2CR
NTS neurons significantly suppresses
feeding and identifies a novel population of NTS cells that may
be targeted for food intake reduction.
Selective 5-HT2CR
NTS/DMV Activation Is Sufficient to
Promote 5-HT2CR Agonist Hypophagia
We next evaluated whether an obesity medication currently
in human use employs the subset of 5-HT2CR
NTS to promote
a reduction in feeding behavior. To exclusively activate
5-HT2CR
NTS with clinical and preclinical obesity medications,
we restricted the expression of the endogenous receptor to
the caudal aspects of the dorsal vagal complex (the NTS and
dorsal motor nucleus of the vagus [DMV]; 5-HT2CR
NTS/DMV).
We achieved this using a reversible 5-HT2CR null line, in which
expression of Htr2cr is prevented by a loxP-flanked transcrip-
tional blocker (Xu et al., 2008). The expression of Htr2cr was
site-specifically reactivated via stereotactic delivery of an AAV-
expressing Cre recombinase (AAV-Cre) into the NTS/DMV,
which removes the transcriptional blocker (Figures 2A and 2B),
allowing 5-HT2CRs expression only in the NTS/DMV (Figures
2C and 2D). To confirm the functional re-expression of Htr2c,
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Figure 2. 5-HT2CR
NTS Is Sufficient to Mediate the Appetite-Suppressive Effect of 5-HT2CR Agonists
(A) Schematic of the strategy used to selectively restore 5-HT2CRs within the NTS of loxTB5-HT2CR null mice through stereotactic injection of Cre-dependent
DREADD vectors into NTS.
(B) 5-HT2CR allele expression is disrupted by a loxP-flanked transcriptional blocker (loxTB) inserted between exons 3 and 4 of the htr2c gene in loxTB5-HT2CR
mice (5-HT2CR
KO). Stereotactic injection of AAV vector expressing Cre recombinase and mCherry reporter driven by the hSyn promoter removes the TB and
allows 5-HT2CR expression only in the NTS (5-HT2CR
NTS/DMV).
(C) Representative image of Cre-mCherry expression within the rostrocaudal aspect of the NTS/DMV.
(D) Cre-mediated recombination of the mutant allele and TB removal specifically within the NTS/DMV in 5-HT2CR
NTS/DMV mice (wild-type band 437 bp,
mutant 310 bp).
(E) Representative current-clamp traces and proportion of neurons responding to bath application of lorcaserin in ex vivo NTS slices prepared from 5-HT2CR
WT
(n = 7), 5-HT2CR
KO (n = 12), and 5-HT2CR
NTS/DMV (n = 8) mice.
(F) Sidak’s post hoc comparisons revealed that lorcaserin andWAY161,503 (7mg/kg, i.p.) reduced ad libitum food intake at specific time points within the first 3 hr
of the dark cycle (tick marks on x axis represent 20-min intervals) in 5-HT2CR
WT (lorcaserin, n = 5; time: F6,24 = 55.19, p < 0.0001; treatment: F1,4 = 16.81,
p = 0.0149; interaction: F6,24 = 8.991, p < 0.0001. WAY161,503, n = 6; time: F6,30 = 53.37, p < 0.0001; treatment: F1,5 = 61.55, p = 0.0005; interaction: F6,30 = 26.16,
p < 0.0001) and 5-HT2CR
NTS/DMVmice (lorcaserin, n = 5; time: F6,24 = 63.53, p < 0.0001; treatment: F1,4 = 23.78, p = 0.0082; interaction: F6,24 = 4.099, p = 0.0057.
WAY161,503, n = 6; time: F6,30 = 51.89, p < 0.0001; treatment: F1,5 = 4.028, p = 0.1010; interaction: F6,30 = 1.878, p = 0.1175), but not 5-HT2CR
KOmice. Data are
presented as mean ± SEM. Sidak’s post hoc comparisons *p < 0.05, **p < 0.01, ***p < 0.001.
NTS, nucleus of the solitary tract; AP, area postrema; CC, central canal; DMV, dorsal motor nucleus of the vagus. See also Figure S2.wemade ex vivowhole-cell electrophysiological recordings from
neurons within NTS slices in 5-HT2CR
WT (wild-type), 5-HT2CR
KO
(knockout), and mice with 5-HT2CRs restored exclusively
within the NTS/DMV (5-HT2CR
NTS/DMV). As expected, NTS
neurons from 5-HT2CR
KO mice failed to respond to lorcaserin,
while similar proportions of NTS neurons from 5-HT2CR
WT and
5-HT2CR
NTS/DMV mice were excited by lorcaserin (Figure 2E).
These data indicate that AAV-Cre restores functional 5-HT2CR
expression in 5-HT2CR
NTS/DMV mice.
Consistent with previous reports, body weight was signifi-
cantly higher in adult 5-HT2CR
KO compared with 5-HT2CR
WT
mice (Nonogaki et al., 2003; Xu et al., 2008); an effect that failed
to normalize following post-developmental re-expression of the
5-HT2CR exclusively within the NTS/DMV (Figure S2A). Further
analysis of energy balance revealed no difference in daily,
nocturnal, or diurnal energy expenditure between genotypes
(Figures S2B and S2C). We were unable to detect the predicted
increase in ad libitum chow intake (Figure S2D) or chow intakefollowing an overnight fast in 5-HT2CR
KO mice (Figure S2E),
which may be related to the previously reported variability in
the magnitude of hyperphagia on a chow diet with age in
5-HT2CR
KO mice (Wade et al., 2008). These results indicate
that restoration of 5-HT2CRs only within the NTS/DMV is not
sufficient to correct the increased body weight phenotype of
chow-fed 5-HT2CR
KO mice.
To test the significance of 5-HT2CR
NTS/DMV in a ther-
apeutic context, we treated 5-HT2CR
WT, 5-HT2CR
KO, and
5-HT2CR
NTS/DMV mice with 5-HT2CR agonists lorcaserin and
WAY161,503. In line with previous research (Burke et al., 2014;
Fletcher et al., 2009), the obesity medication lorcaserin and the
preclinical compound WAY161,503 significantly reduced ad libi-
tum food intake in 5-HT2CR
WT mice compared with saline treat-
ment (Figure 2F). This effect was absent in 5-HT2CR
KO mice but
predominantly restored in 5-HT2CR
NTS/DMV mice (Figure 2F).
Thus, consistent with chemogenetic activation of 5-HT2CR
NTS
cells, pharmacological activation of this discrete subset of cellsCell Metabolism 28, 619–630, October 2, 2018 621
has a significant impact on feeding behavior. These data also
reveal that 5-HT2CRs expressed within the NTS/DMV are suffi-
cient to mediate acute therapeutic effects of a medication
currently in clinical use to treat obesity, thereby highlighting
a specific subset of 5-HT2CRs that may be exploited for future
obesity medication development.
5-HT2CR Agonists Directly Activate POMC
NTS Cells
We next interrogated the neurochemical phenotype of
5-HT2CR
NTS cells to probe the mechanism through which
5-HT2CR
NTS-mediated effects on appetite are achieved. Though
POMC neurons within the ARC have been proposed to be a
primary mediator of 5-HT2CR’s effects on metabolic functions
(Berglund et al., 2013; Burke et al., 2014, 2017; Doslikova
et al., 2013; Heisler et al., 2002; Xu et al., 2010), a smaller and
less well characterized population of POMC expressing neurons
reside within the caudal aspect of the NTS (POMCNTS), a region
receiving inputs from vagal afferent fibers that transmit meal-
related information from the gastrointestinal system (Appleyard
et al., 2005; Fan et al., 2004; Joseph et al., 1983; Zhan
et al., 2013). We thus hypothesized that POMCNTS is a functional
component of 5-HT2CR
NTS-mediated hypophagia.
To visualize anatomical expression, we utilized PomcDsRED re-
porter mice (Hentges et al., 2009) and fluorescent in situ hybrid-
ization to label endogenous 5-HT2CRmRNA. Althoughmore than
one-third (38.2% ± 1.3%) of POMCNTS cells express 5-HT2CR
mRNA, POMCNTS neurons represent only a small (approximately
4%) subset of the total NTS 5-HT2CRmRNA-expressing popula-
tion (Figure 3A). Next, to evaluate the impact of 5-HT2CR activa-
tion on POMCNTS neuronal activity, we performed whole-cell
electrophysiological recordings in PomcDsRED NTS slices.
Consistent with the anatomical co-expression profile, 45.5%
(10/22) of PomcDsRED cells were responsive to 5-HT (10 mM),
the endogenous 5-HT2CR agonist (Figures 3B and 3C). A similar
proportion of responders was observed following application of
5-HT2CR agonists lorcaserin (20 mM) and WAY161,503 (20 mM),
with 47.1% (8/17) and 50% (11/22) of PomcDsRED cells respond-
ing, respectively (Figures 3B and 3C). All responseswere charac-
terized by depolarization and commencement/enhancement of
action potential discharge. These effects were independent of
action potential-dependent synaptic transmission, as depolar-
izations endured in the presence of 500 nM tetrodotoxin (TTX)
(5-HT, 13.2 ± 3.8 mV, n = 7; lorcaserin, 11.7 ± 3.6 mV, n = 7;
WAY161,503, 12.8 ± 2.7 mV, n = 8; Figure 3C), indicating that
5-HT and 5-HT2CR agonists directly activate POMC
NTS cells
via a post-synaptic mechanism. 5-HT and 5-HT2CR agonists
induced a similar degree of depolarization and activated a similar
percentage of POMCNTS cells (Figure 3D). These data reveal that
5-HT2CRs are anatomically positioned to increase the activity of
a subset of POMCNTS cells.
To examine the post-synaptic ionic mechanisms underpinning
the excitatory effects of 5-HT and lorcaserin, we recorded
POMCNTS neurons in a voltage clamp (VC) and in the presence
of TTX. At a holding potential of 60 mV, application of 5-HT
(10 mM) induced a reversible inward current of 23.1 ± 2.5 pA
(n = 10; Figure 4A). The current-voltage relationship of I5-HT was
examined using VC ramps, which drove the membrane potential
from120mV to 0mVat a rate of 45.7mV s1 (Figure 4B; n = 10).
The digital subtraction of the ramp in control from the ramp at the622 Cell Metabolism 28, 619–630, October 2, 2018peak of the response revealed I5-HT to be outwardly rectifying and
to reverse at27.0 ± 3.6 mV (Figure 4C; n = 10). Likewise, lorca-
serin (20 mM) induced an inward current of15.5 ± 2.5 pA (n = 12;
Figure 4D) that was shown to be outwardly rectifying and to
reverse at 24.6 ± 2.9 mV (Figures 4E and 4F). These data illus-
trate that 5-HT and lorcaserin excite POMCNTS neurons via the
activation of a post-synaptic, mixed cationic current. This mech-
anism is consistent with that observed for 5-HT2CR activation of
POMCARC neurons (Sohn et al., 2011).
Brain POMC Is Necessary to Mediate 5-HT2CR Agonist
Feeding Effects
Thus far, we have established that the 5-HT2CRs are anatomically
positioned to influence the activity of approximately 40% of
POMCNTS neurons and previous reports indicate that 5-HT2CRs
are co-expressed with approximately 40% of POMCARC neurons
(Heisler et al., 2002; Lam et al., 2008). Earlier transgenic ap-
proaches have revealed that the subset of 5-HT2CRs that are
necessary and sufficient for 5-HT2CR agonists to reduce food
intake are co-expressed with POMC (Berglund et al., 2013; Xu
et al., 2008). These approaches manipulate the expression of
the receptor, not POMC production. We aimed to determine the
function of POMC in lorcaserin’s anorectic effect. As a first step
toward this goal, we employed amousemodel with full POMCARC
knockout and approximately half POMCNTS knockdown
(PomcNEO) (Bumaschny et al., 2012). PomcNEO and wild-type
(PomcWT) littermates were treated with saline or lorcaserin
(7 mg/kg, i.p.) at the onset of the dark cycle and ad libitum home
cage chow intake was measured 1, 3, and 6 hr later. As
expected, PomcWT mice treated with lorcaserin significantly
reduced food intake compared with saline-treated littermates at
each time point (Figure 5A). However, lorcaserin did not have a
significant effect on food intake at any of these time points in
PomcNEO mice compared with saline-treated littermates
(Figure 5B). These results were replicated in further cohorts of
PomcNEO and PomcWT littermates using a within-subjects exper-
imental design (data not shown). These data reveal that brain
POMC is required for lorcaserin to promote its effects on food
intake.
POMCARC Is Required for the Full Effect of 5-HT2CR
Agonist on Food Intake
We next sought to determine the functional significance of
the discrete subset of POMCNTS versus POMCARC in 5-HT2CR
agonist-induced reduction of food intake. We first targeted
Pomc in the hypothalamus, since this population of Pomc ex-
pressing neurons is larger, better characterized, and projects
widely within the hypothalamus, allowing efficient tissue sam-
pling and recovery of peptides that localize at neuron terminals
(e.g., POMC-derived peptide a-melanocyte-stimulating hor-
mone [a-MSH] [D’Agostino and Diano, 2010]). To knock down
POMCARC, we employed the clustered, regularly interspaced,
short palindromic repeats (CRISPR) and associated endonu-
clease 9 (Cas9) gene-editing technique (Doudna and Charpent-
ier, 2014; Hsu et al., 2014). Specifically targeted by synthetic
guide RNA (sgRNA) sequences, Cas9-induced double-stranded
breaks typically result in frameshifting insertion/deletions (indels)
owing to the action of non-homologous end-joining (NHEJ) DNA
repair mechanisms, leading to disruption of the encoded protein.
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Figure 3. 5-HT and 5-HT2CR Agonists Directly Activate POMC
NTS Neurons
(A) Representative image illustrating 38% of DsRED-positive POMCNTS neurons (red) express 5-HT2CRmRNA (green; co-expressed, yellow) in Pomc
DsRED mice.
Scale bar, 200 mm; inset scale bar, 50 mm.
(B) Representative current-clamp recordings of POMCNTS neurons in slices from PomcDsRED mice following (i) 10 mM 5-HT, (ii) 20 mM lorcaserin, (iii) and 20 mM
WAY161,503.
(C) (i) 5-HT (n = 7; F2,18 = 12.9, p = 0.001), (ii) lorcaserin (n = 7; F2,18 = 8.2, p = 0.006), and (iii) WAY161,503 (n = 8; F2,21 = 10.3, p = 0.002) elicit a significant and
reversible change inmembrane potential (recorded in 500 nM TTX and from an initial membrane potential of65mV, a value achieved through the injection of DC
current). Thick lines represent mean ± SEM; dashed lines, raw data. ***p < 0.001.
(D) Summary of membrane potential changes induced by 5-HT, lorcaserin, andWAY161,503. Boxes represent 25th, 50th, and 75th percentile with superimposed
mean ± SEM and maximum and minimum values.
NTS, nucleus of the solitary tract; AP, area postrema; CC, central canal.Following an in vitro screening of selected sgRNAs targeting the
third exon of the Pomc gene, Cas9-induced indels at the pre-
dicted positions were detected using a T7 endonuclease I assay
(Figure 6A). Two active sgRNAs were cloned into an AAV vector
that also expressed eGFP to enable site-specific brain delivery
(Swiech et al., 2015).
AAVs expressing Pomc-targeting Cas9 and sgRNA-eGFP
(PomcARC-CRISPR) or AAVs expressing sgRNA-eGFP alone(PomcARC-WT) were then stereotactically injected into the ARC
(Figure 6B). Quantitative analysis of hypothalamic a-MSH content
revealedPomcARC-CRISPRmice had an approximately 60% reduc-
tion in a-MSH (Figure 6C). To control for the occurrence of
CRISPR/Cas9-induced indels, we implemented a method allow-
ing ex vivo detection of DNA heteroduplexes. This is a widely
used proxy of indel occurrence in vitro. Genomic DNA from
PomcARC-CRISPR and PomcARC-WT mice was extracted and theCell Metabolism 28, 619–630, October 2, 2018 623
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Figure 5. Brain POMC Is a Necessary Neurochemical Mediating 5-HT2CR Agonist Feeding Effects
(A) Male and female wild-type mice (PomcWT) treated with lorcaserin (7 mg/kg, i.p.) significantly reduced 1-, 3-, and 6-hr dark cycle food intake compared with
saline-treated PomcWT littermates (n = 11 per group; 1 hr: t20 = 2.884, p = 0.0092; 3 hr: t20 = 2.916, p = 0.0085; 6 hr: t20 = 3.373, p = 0.0030).
(B) In contrast, male and female mice with full POMCARC knockout and partial POMCNTS knockdown (PomcNeo) exhibited a blunted response to lorcaserin
treatment as compared with PomcNeo littermates treated with saline (n = 6–7 per group; 1 hr: t11 = 1.3204, p = 0.216; 3 hr: t11 = 0.4098, p = 0.6898; 6 hr:
t11 = 0.9486, p = 0.3632).
Data are presented as mean ± SEM. **p < 0.01.third exon of the Pomc gene was amplified by PCR. Subsequent
PAGE analysis revealed that DNA heteroduplexes were exclu-
sively in samples obtained from the mediobasal hypothalamus in
PomcARC-CRISPR mice. DNA heteroduplexes were not found in
the hypothalamus of PomcARC-WT mice (Figure 6D). Behaviorally,
PomcARC-CRISPR mice displayed phenotypes consistent with
reduced POMCARC function, including hyperphagia following
food deprivation (Figure 6E) and greater operant responding
for palatable food (Figure 6F). Next, we assessed the role of
POMCARC in lorcaserin’s effects on food intake. As expected,
lorcaserin significantly reduced ad libitum dark cycle food
intake compared with saline treatment in PomcARC-WT mice
when analyzed over the first 3 hr of the dark cycle (Figure 6G,
left) and as cumulative 3 and 6 hr of food intake (Figure 6G, right).
In contrast, PomcARC-CRISPR mice only significantly responded to
the acute anorectic effect of lorcaserin (Figure 6H, left). Analysis
of 3- and 6-hr cumulative intake revealed that PomcARC-CRISPR
mice exhibited an attenuated response to lorcaserin. Specifically,
lorcaserin did not significantly alter food intake compared with
saline treatment at either time point in PomcARC-CRISPR mice
(Figure6H, right).One interpretationof thesedata is thatPOMCARC
is not a principal mediator of lorcaserin’s acute effects on food
intake; rather, it is necessary for the longer-term effect. How-
ever, it is possible that the acute response to lorcaserin in
PomcARC-CRISPR mice is due to incomplete knockdown of
POMCARC and that the subset remaining is sufficient for lorcaserin
to reduce feeding at this earlier time point. Nevertheless, theseFigure 4. 5-HT and 5-HT2CR Agonists Activate POMC
NTS Neurons Via
(A) Representative voltage-clamp recording of a POMCNTS neuron from PomcD
results in an inward current (scale bar, 20 s). To the right, sharing its y axis with the
distributions in control (green), 5-HT (red), andwash (black). Raw data used to prod
hoc Tukey test, ***p < 0.001).
(B) Averaged voltage-clamp ramps (n = 10) acquired in control (green) and at the
(C) 5-HT-induced current (I5-HT) obtained by the digital subtraction of the traces di
shading the SEM.
(D) Representative voltage-clamp recording of a POMCNTS neuron in the presence
20 s). To the right, sharing its y axis with the raw trace, are Gaussian fits of avera
lorcaserin (blue). Raw data used to produce averages shown as dashed lines (n
(E) Averaged voltage-clamp ramps (n = 12) acquired in control (green) and at the
(F) Lorcaserin-induced current (ILorcaserin) obtained by the digital subtraction of t
denotes mean, shading the SEM.data indicate that lorcaserin requires functional Pomc within the
ARC to promote its full effect on food intake.
POMCNTS Is Required for the Acute Effect of 5-HT2CR
Agonists on Food Intake
We next examined the functional significance of POMCNTS in the
therapeutic effects of 5-HT2CR agonist obesity medications.
We created two cohorts of mice by stereotactically delivering
AAVs expressing Pomc-targeting Cas9 and sgRNA-eGFP
(PomcNTS-CRISPR) or AAVs expressing sgRNA-eGFP alone
(PomcNTS-WT) to the NTS (Figures 7A and 7B). Since a-MSH
expression from NTS explants is not at a high enough level for
reliable measurement, we adopted the method used above for
PomcARC-CRISPR validation, allowing ex vivo detection of DNA het-
eroduplexes to control for the occurrence of CRISPR/Cas9-
induced indels. Genomic DNA from PomcNTS-CRISPR and
PomcNTS-WT mice was extracted and the third exon of the Pomc
genewas amplified by PCR. Subsequent PAGE analysis revealed
that DNA heteroduplexes were exclusively in samples obtained
from the NTS/DMV and not an internal control region in
PomcNTS-CRISPRmice (Figures7Cand 7D). As expected,DNAhet-
eroduplexes were not found in either the NTS/DMV or an internal
control region of PomcNTS-WT mice (Figure 7C). These data sug-
gest thatPomchas been successfully targeted inPomcNTS-CRISPR
mice, although this method does not provide quantification of the
degree of knockdown. As expected, lorcaserin andWAY161,503
significantly reduced ad libitum dark cycle food intake inPost-synaptic, Mixed Cationic Current
sRED NTS slices in the presence of TTX (500 nM). Application of 5-HT (10 mM)
raw trace, are Gaussian fits of averaged (solid lines) holding current frequency
uce averages shown as dashed lines (n = 10, F2,27 = 18.1, p = 1.023 10
5; post
peak of response (red). Line denotes mean, shading the SEM.
splayed in (B). Note the reversal at27.0 ± 3.6 mV (n = 10). Line denotes mean,
of TTX. Application of lorcaserin (20 mM) results in an inward current (scale bar,
ged (solid lines) holding current frequency distributions in control (green) and
= 13, t12 = 6.2, p = 4.5 3 10
5, t-test paired, ***p < 0.001).
peak of response (blue). Line denotes mean, shading the SEM.
he traces displayed in (E). Note the reversal at 24.6 ± 2.9 mV (n = 12). Line
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Figure 6. PomcARC Is Required for 5-HT2CR Agonist Hypophagia
(A) Representative screening of sgRNAs targeting the exon 3 of the Pomc gene in Neuro2A cells and indels detection using a T7 endonuclease I assay. (A, left)
Sites of potential indels in exon 3 are indicated by red or green bars, and the presence of indels results in the fragments indicated by red or green asterisks,
respectively, following endonuclease treatment. (A, right) Bands corresponding to these fragments are indicated with red and green asterisks on the gel.
(B) Schematic of bilateral mediobasal hypothalamic stereotactic delivery of AAVs expressing Pomc-targeting CRISPR/Cas9 and EGFP (PomcARC-CRISPR).
Representative image of GFP within the arcuate nucleus of the hypothalamus (ARC) third ventricle (3V).
(C) Hypothalamic content of Pomc peptide product a-melanocyte-stimulating hormone (a-MSH) 6 weeks after AAV injection is significantly reduced asmeasured
by quantitative fluorescent EIA assay in PomcARC-CRISPR mice compared with controls injected with AAV-expressing sgRNA-eGFP alone (PomcARC-WT), illus-
trating that in vivo CRISPR targeting knocked down Pomc in the ARC (p = 0.0059; Mann-Whitney test).
(D) PAGE analysis identified heteroduplexes (pink arrowheads) from exon 3 of Pomc amplified from the mediobasal hypothalamus of PomcARC-CRISPR mice.
(E)PomcARC-CRISPRmiceexhibit24hrofhyperphagia forhomecagechowfollowing food restrictioncomparedwithPomcARC-WTmice (n=7–8;F1,13=11.27,p=0.005).
(F) Likewise, PomcARC-CRISPR mice show greater motivation to work for palatable food compared with PomcARC-WT mice as assessed by the breakpoint of lever
presses for chocolate pellets using a progressive-ratio schedule (n = 7–8; t12 = 2.463, p = 0.029).
(G) (Left) Lorcaserin (7 mg/kg, i.p.) reduced acute food intake within the first 3 hr (tick marks on x axis represent 20-min intervals) of the dark cycle in PomcARC-WT
mice (n = 7; time: F9,54 = 38.05, p < 0.0001; treatment: F1,6 = 39.94, p = 0.0007; interaction: F9,54 = 13.91, p < 0.0001) and (right) as analyzed as total 3- and 6-hr
cumulative intake (time: F1,6 = 169.7, p < 0.0001; treatment: F1,6 = 11.22, p = 0.0154; interaction: F1,6 = 0.8351, p = 0.3960).
(H) (Left) Lorcaserin (7 mg/kg, i.p.) also reduced acute food intake within the first 3 hr in PomcARC-CRISPR mice (n = 10; time: F9,81 = 168.1, p < 0.0001; treatment:
F1,9 = 16.46, p = 0.0029; interaction: F9,81 = 2.108, p = 0.0381). (Right) However, lorcaserin was not effective in reducing cumulative food intake compared with
saline treatment in PomcARC-CRISPR mice when analyzed at 3 or 6 hr food intake with Sidak’s post hoc comparisons (n = 10; time: F1,9 = 130.8, p < 0.0001;
treatment: F1,9 = 110.44, p = 0.0103; interaction: F1,9 = 0.01045, p = 0.9208).
Data are presented as mean ± SEM. Sidak’s post hoc comparisons *p < 0.05, **p < 0.01.
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Pomc
NTS-WT
mice over 6 hr (Figures 7E and 7G). However, following
administration of 5-HT2CR agonists, Pomc
NTS-CRISPR mice ex-
hibited an attenuated anorectic response to both lorcaserin and
WAY161,503 during the first 3 hr of the dark cycle (Figure 7F).
This attenuated effect to lorcaserin and WAY161,503 did not
persist for the full 6 hr in PomcNTS-CRISPR mice. Lorcaserin signifi-
cantly reduced 6-hr cumulative intake in PomcNTS-CRISPR mice
compared with saline treatment (Figure 7H). Taken together with
the PomcNEO and PomcARC-CRISPR results, these data suggest
that POMCNTS is required for the acute effect of lorcaserin on
food intake, whereas POMCARC is required for the longer-term ef-
fect on feeding. These findings are generally consistent with pre-
vious reports using chemogenetic and optogenetic approaches
to examine POMCneuron function, which suggest that POMCARC
and POMCNTS neurons affect feeding on different time scales
(Aponte et al., 2011; Koch et al., 2015; Zhan et al., 2013).
DISCUSSION
Obesity negatively affects human health on a global scale. If we
are to meet this challenge and design new medications, it is
paramount that we gain a more complete understanding of
the mechanisms regulating food intake and body weight. The
5-HT2CR agonist lorcaserin is a current obesity medication; how-
ever, neither the specific subset of 5-HT2CRs coordinating the
therapeutic effect nor the neurochemical mediator targeted by
these receptors has been fully defined. Earlier research geneti-
cally manipulating the receptor revealed that the subset of
5-HT2CRs co-expressed with brain POMC are both sufficient
(Xu et al., 2010) and necessary (Berglund et al., 2013) to modu-
late the anorectic effect of preclinical 5-HT2CR agonists. Given
that 5-HT2CR agonists increase the activity of POMC
ARC neurons
(Burke and Heisler, 2015; Doslikova et al., 2013; Heisler et al.,
2002), it was presumed that these neurons were the mediator
of this effect. However, in light of recent findings that POMCARC
neurons suppress appetite on a time scale of hours (Aponte
et al., 2011; Koch et al., 2015; Zhan et al., 2013), we considered
whether 5-HT2CRs outside the ARC are necessary for 5-HT2CR’s
acute effects on feeding. Here we identify the function of a pre-
viously uncharacterized subset of 5-HT2CR expressing neurons,
localized within the NTS, and reveal that the activation of this
subpopulation has a significant and rapid impact on feedingFigure 7. PomcNTS Is Required for 5-HT2CR Agonist Hypophagia
(A) AAV-mediated strategy to express in the nucleus of the solitary tract (NTS) Pom
of AAVs expressing Pomc-targeting CRISPR/Cas9 and EGFP (PomcNTS-CRISPR).
(B) Representative image of eGFP expression within the dorsal vagal complex (D
(C) PAGE analysis identified heteroduplexes (pink arrowheads) from exon 3 of P
(D) Representative image of tissue samples taken from the NTS and broader dor
(E and F) 5-HT2CR agonists lorcaserin andWAY161,503 (7mg/kg, i.p.) reduced ac
x axis represent 20-min intervals) of the dark cycle (lorcaserin, n = 8; time: F9,63 = 1
p < 0.001.WAY161,503, n = 8; time: F9,63 = 54.95, p < 0.0001; treatment: F1,7 = 24.
mice (F) (lorcaserin, n = 7; time: F9,54 = 38.39, p < 0.0001; treatment: F1,6 = 0.1580
F9,54 = 62.69, p < 0.0001; treatment: F1,6 = 2.444, p = 0.1690; interaction: F9,54 =
(G) Likewise, when analyzed as total cumulative 3- and 6-hr dark cycle intak
PomcNTS-WT mice (lorcaserin, n = 8; time: F1,7 = 96.71, p < 0.0001; treatment: F1,7
time: F1,7 = 62.88, p < 0.0001; treatment: F1,7 = 17.53, p = 0.0041; interaction: F
(H) POMCNTS knockdown in PomcNTS-CRISPR mice prevented the acute 3-hr anore
6 hr post treatment as analyzed with Sidak’s post hoc comparisons (lorcaserin
interaction: F1,6 = 5.309, p = 0.0608. WAY161,503, n = 7; time: F1,6 = 66.68, p = 0.0
Data are presented as mean ± SEM. Sidak’s post hoc comparisons *p < 0.05, **
628 Cell Metabolism 28, 619–630, October 2, 2018behavior, and furthermore is sufficient to drive lorcaserin’s acute
reduction in food intake. In addition, we report that a subset
of POMCNTS neurons express 5-HT2CRs and that 5-HT and
5-HT2CR agonists directly activate POMC
NTS neurons via a
post-synaptic, mixed cationic current. We also clarify that brain
POMC is necessary for lorcaserin to influence feeding. Although
POMC is not abundantly expressed within the NTS, we report
that POMC in this region is required for 5-HT2CR agonist obesity
medications to acutely reduce food intake. These data thereby
reveal a subpopulation of 5-HT2CRs, which when pharmacolog-
ically activated significantly reduce food intake, identify that the
mechanistic underpinnings of this acute effect is via POMCNTS,
and demonstrate that this discrete 5-HT2CR
NTS subpopulation
is therapeutically relevant to obesity medications targeting the
5-HT2CRs.
Limitations of Study
It is possible that the results obtained are affected by incomplete
knockdown of Pomc in the ARC and NTS. Although altering
POMCNTS expression significantly attenuated the acute effect
of lorcaserin on food intake, at baseline PomcNTS-CRISPR mice
displayed food intake comparable with PomcNTS-WT mice during
ad libitum feeding (Figures 7E and 7F; and data not shown).
These data are consistent with a previous report of diphtheria
toxin POMCNTS cell ablation in a PomcCre mouse line, which
did not produce an effect on ad libitum food intake (Zhan et al.,
2013). However, we cannot exclude the possibility that this
absence of baseline phenotype PomcNTS-CRISPR mice is due to
incomplete knockdown of PomcNTS. Further studies are required
to fully interrogate the physiological role of POMCNTS. Neverthe-
less, our data reveal that the relatively small source of POMC
specifically derived within the NTS is necessary for the
obesity medication lorcaserin and the preclinical compound
WAY161,503 to promote their full effects on feeding behavior.
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Antibodies
Chicken anti-GFP AbCam Cat# ab13970; RRID: AB_300798
Rabbit anti-dsRED Rockland Cat# 600-401-379; RRID: RRID:
AB_2209751
Rabbit anti-c-FOS Calbiochem Cat# PC38; RRID:AB_2106755
Goat mCherry (RFP) Sicgen Cat# AB0040-200; RRID:AB_2333092
Donkey polyclonal anti-chicken alexa 488 Jackson ImmunoResearch Cat# 703-545-155; RRID: AB_2340375
Goat anti-Rabbit IgG Secondary Antibody,
Alexa Fluor 594
Life Technologies Cat# A-11012, RRID:AB_141359
Donkey anti-Goat IgG Secondary Antibody,
Alexa Fluor 594
Life Technologies Cat# A-11057; RRID:AB_142581
Biotin-SP-AffiniPure F(ab’)2 Fragment
Donkey Anti-Rabbit IgG
Jackson ImmunoResearch Cat# 711-066-152, RRID:AB_2340594
Streptavidin, Alexa Fluor 568 conjugate antibody Life Technologies Cat# S-11226, RRID:AB_2315774
Bacterial and Virus Strains
One Shot Stbl3 Chemically Competent E. coli Invitrogen Cat# C737303
AAV8-hSyn-DIO-hM3Dq-mCherry University North Carolina Vector Core N/A
AAV8-hSyn-DIO-hM4Di-mCherry University North Carolina Vector Core N/A
AAV8-hSyn-mCherry-Cre University North Carolina Vector Core N/A
AAV-U6sgRNA(SapI)_hSyn-GFP-KASH-bGH Unitat de Produccio´ de Vectors,
Universitat Autonoma Barcelona, Spain
N/A
AAV/DJ-CMV-spCas9 Vector Biolabs Cat# 7120
Chemicals, Peptides, and Recombinant Proteins
Clozapine-N-oxide (CNO) Tocris Bioscience Cat. No. 4936; CAS: 34233-69-7
Lorcaserin Hydrochloride LGM Pharma Cat# 846589-98-8
Lot# 20130115
WAY 161503 hydrochloride Tocris Bioscience Cat. No. 1801; CAS: 276695-22-8
Critical Commercial Assays
In-Fusion HD cloning Kit Clonotech Laboratories Cat No. 638910
Plasmid plus Maxi kit QIAGEN Cat No. 12943
QIAquick Gel Extraction Kit QIAGEN Cat No. 28704
FuGENE HD Transfection Reagent Promega Cat No E2311
PureLink Genomic DNA Mini Kit Invitrogen Cat No K182001
Surveyor Mutation Detection Kit Integrated DNA Technologies Cat No. 706020
MSH, alpha EIA kit Phoenix Pharmaceutical Inc. Cat No FEK-043-01
Experimental Models: Cell Lines
Neuro-2a (N2a) cells ATCC CCL-131
Experimental Models: Organisms/Strains
Mouse: 5-HT2CR-ires
Cre Burke et al., 2016; Marcinkiewcz
et al., 2016
N/A
Mouse: POMCdsRed Hentges et al., 2009 N/A
Mouse: POMCNEO Bumaschny et al., 2012 N/A
Mouse: loxtb5-HT2CR (B6.129-Htr2c
tm1Jke/J) Jackson Laboratory JAX: 015821
Mouse: C57BL/6J Jackson Laboratory JAX: 000664
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Oligonucleotides
Genomic DNA Pomc PCR primer F:
GCTTGCATCCGGGCTTGC
This paper N/A
genomic DNA Pomc PCR primer R:
GACTTTATTTACGCAGTTTTTATTGAAGATCAGAGC
This paper N/A
Pomc gRNA1:
GGTGGGCAAGAAACGGCGCC
This paper N/A
Pomc gRNA2:
GTGACCCATGACGTACTTCCG
This paper N/A
Recombinant DNA
pX330-U6-Chimeric_BB-CBh-hSpCas9 (PX330) Addgene Addgene Plasmid #42230
pAAV-U6sgRNA(SapI)_hSyn-GFP-KASH-bGH (PX552) Addgene Addgene Plasmid #60958
cDNA HTR2C cDNA Julius et al., 1988 N/A
Software and Algorithms
pClamp10 software Molecular Devices
CRISPR Design Zhang Lab, MIT http://crispr.mit.edu/
PhenoMaster TSE https://www.tse-systems.com/product-
details/phenomaster
MATLAB Mathworks https://www.mathworks.com/
Prism6 GraphPad https://www.graphpad.com/scientific-
software/prism/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to the Lead Contact Lora Heisler (lora.heisler@abdn.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
5-HT2CR-ires
Cre (Burke et al., 2016; Marcinkiewcz et al., 2016), loxtb5-HT2CR (B6.129-Htr2c
tm1Jke/J; The Jackson Laboratory, Bar
Harbor, ME USA), PomcDsRED (Hentges et al., 2009) and PomcNEO (Bumaschny et al., 2012) mice were housed with ad libitum
food and water access (unless otherwise stated) in a light- (12 h on/12 h off) and temperature-controlled (21.5C to 22.5C) environ-
ment. All procedures were performed in accordance with the U.K. Animals (Scientific Procedures) Act 1986 and local ethical
approvals.
METHOD DETAILS
Stereotaxic Surgery and Viral Vectors
Viral constructs were packaged in AAV serotype-8 and were delivered to the NTS via bilateral stereotaxic injections, as previously
described (D’Agostino et al., 2016).
AAV vectors
The DREADD viruses used have been described previously: AAV8-hSyn-DIO-hM3Dq-mCherry, AAV8-hSyn-DIO-hM4Di-mCherry
and AAV8-hSyn-mCherry-Cre were packaged in AAV serotype-8 at a titer of 1.3 x 1013 vg/ml (University North Carolina Vector
Core, Chapel Hill, NC, USA) (Krashes et al., 2011; D’Agostino et al., 2016). AAV/DJ-CMV-spCas9 was obtained from Vector Biolabs
(Cat No. 7120; Vector Biolabs, Malvern, PA, USA). High titer pAAV-U6sgRNA(SapI)_hSyn-GFP-KASH-bGH (PX552) were packaged
in AAV serotype-8 at a titer of 4.1 x 1012 vg/ml (Unitat de Produccio´ de Vectors, Universitat Autonoma Barcelona, Spain).
Stereotaxic Surgery
NTS delivery of AAVs was achieved through a stereotaxic procedure. Briefly, 5–8 week old male mice were anesthetized with a
mixture of ketamine and xylazine dissolved in saline (100 and 10 mg/kg, respectively injected in a volume of 10 ml/kg, i.p.). Mice
were placed in a stereotaxic frame (Kopf Instruments, Tujunga, CA USA) using ear bars with the head angled at 45. Under magni-
fication, an incision was made at the level of the cisterna magna and neck muscles carefully retracted. A 33G needle was used for
dura incision. The obex served as reference point for injection. Bilateral injections were performed using a glass micropipette
(diameter 20–40 mm). NTS coordinates used were A/P, -0.2; M/L, ±0.2; D/V, -0.2 from the obex. Virus was delivered under air
pressure using a PLI-100A Pico-Injector (Harvard Apparatus, Cambridge, UK). 150 nl of virus per side was delivered with multiplee2 Cell Metabolism 28, 619–630.e1–e5, October 2, 2018
microinjections over 4–5 minutes. The pipette remained in place for a minimum of 3 minutes after injection. Following all surgery, an-
imals were closely monitored, kept warm and appropriate postsurgical care was taken. Animals were also administered an analgesic
(5 mg/kg carprofen, s.c.) daily for 2 days post-operatively. Prior to experimentation, mice were acclimated to handling and i.p.
injections.
Mice were given a minimum of 14 days of surgical recovery before experimentation. For chemogenetic experiments, mCherry was
visualised by immunohistochemistry. Mice in which the expression of reporter fluorescent protein was bilaterally detected in the
caudal aspect of the DVCwere included in the analysis, whereas mice without reporter fluorescent expression or expression outside
the DVCwere excluded from the analysis. Caudal DVCwas defined by the presence of the area postrema in the same section of brain
tissue.
DNA Constructs
For SpCas9 target selection and generation of single guide RNA (sgRNA), the 20-nt target sequences were selected to precede a
5’-NGG protospacer-adjacent motif (PAM) sequence. To minimize off-targeting effects, the CRISPR design tool was used (http://
crispr.mit.edu/). The 20-nt target and complement sequences were synthesized to include BbsI overhangs. Oligos were annealed,
phosphorylated and ligated into the pX330-U6-Chimeric_BB-CBh-hSpCas9 (PX330; Addgene plasmid #42230) plasmid after BbsI
digestion.
pAAV-U6sgRNA(SapI)_hSyn-GFP-KASH-bGH (PX552; Addgene plasmid # 60958) was used for cloning sgRNAs into AAV the
backbone and generate viral particles. The plasmid was first digested with SapI to create sticky ends for ligation. The 20-nt target
and complement sequences were synthesized to include SapI overhangs and ligated. A second sgRNA was then inserted into
this vector. The second sgRNA was first PCR-amplified from PX330. Primers were designed to include 15bp homology arms to
the PspOMI-lineraised PX552 into the PCR clone sgRNA guide. The PCR product was column-purified and then cloned into the
PspOMI-lineraised PX552 vector via homologous recombination-assisted cloning (In-Fusion HD cloning Kit, Cat No. 638910; Clo-
notech Laboratories). Primers sequences: AGACTGCAGAGGGCCGAGGGCCTATTTCCCATGATTCCT, forward; CTCATACGCAGG
GCCCTAAAACAAAAAAGCACCGACTCGG, reverse. All obtained constructs were verified by sequencing. All plasmids were ampli-
fied using One Shot Stbl3 Chemically Competent E. coli (Cat No. C737303; Invitrogen) and column-purified (Cat No. 270104;
Qiagen).
Pomc targeting sgRNAs (5’ to 3’): sgRNA 1- GGTGGGCAAGAAACGGCGCC(cgg); sgRNA 2- GTGACCCATGACGTACTTC
CG(ggg).
Cell Line Culture and Transfection
Mouse Neuro-2a (N2a) cells were grown in DMEM containing 10% FBS. Cells were maintained at 37C in 5% CO2 atmosphere.
Transfection were performed using FuGENE  HD Transfection Reagent (Cat No E2311; Promega) according to the manufacturer’s
protocol. Briefly, 1.5x104 cells per well were plated into a 12 well plate the day before transfection. 1 ug of PX330 plasmid was mixed
with Fugene HD in Optimem medium (ratio 1:3). Cells were incubated for 48 hours. Genomic DNA was extracted from transfected
cells using PureLink Genomic DNA Mini Kit (Cat No K182001, Invitrogen) following the manufacturer’s instructions.
Detection of Insertions/Deletions (Indels)
The third exon of the mouse Pomc gene was PCR amplified from genomic DNA using the following primers: GCTTGCATC
CGGGCTTGC, forward; GACTTTATTTACGCAGTTTTTATTGAAGATCAGAGC, reverse. This PCR reaction generates a single PCR
product of the expected 726bp size. PCR product was sequence verified. To detect sgRNA/spCas9-induced indels, genomic
DNA from cells was amplified using the same primers and this 726bp product corresponding to third exon of the mouse Pomc
gene was used for the endonuclease I assay (Surveyor Mutation Detection Kit; Cat No. 706020; Integrated DNA Technologies)
following the manufacturer’s instructions. Briefly, PCR amplicons were heat-denaturated and re-annealed using a thermocycler to
create DNA heteroduplexes. DNA heteroduplexes were incubated with endonuclease I enzyme, which cleaves DNA at the site of
a base mismatch with high specificity, for 1 hour at 42C. Genomic modifications were verified using gel agarose electrophoresis.
Feeding Studies
Dark Cycle Food Intake
Mice were injected with vehicle or drug 30 minutes prior to the onset of the dark cycle and food was removed. At the onset of dark,
food was returned and manually (home cage) or automatically (Phenomaster chambers, TSE, Bad Homburg, Germany) weighed
using methods previously described (D’Agostino et al., 2016).
Post-fast Refeeding
Food was removed at the onset of the dark cycle and returned 2 hours after the onset of the light cycle the following day. Food
intake was measured manually (home cage) or automatically (TSE Phenomaster chambers) using methods previously described
(D’Agostino et al., 2016).
Progressive Ratio
Mice were trained in operant chambers housed in sound-attenuating boxes and controlled by a PC Med-PC-IV programming
language (MED Associates, Inc., Fairfax, VT USA). Chambers (21.6 cm long3 17.8 cmwide3 12.7 cm high) have a retractable lever,
a pellet receptacle and a 3 watt house-light on the opposite wall (Cat No. MED-307W-D1, MED Associates, Inc.). Under food
restriction, mice were trained to press the lever for 20 mg chocolate pellet reinforcers (TestDiet, St. Louis, MO USA) under a fixed
ratio (FR) 1 schedule for 3 days followed by FR 5 for a further 3 days. Then they were fed ad libitum and underwent daily training under
a PR schedule based on an exponential progression derived from the formula (5 3 e0.2n)5, rounded to the nearest integer,Cell Metabolism 28, 619–630.e1–e5, October 2, 2018 e3
where n is the position in the ratio sequence (Richardson and Roberts, 1996). 50 minute sessions took place at the same time each
day during the light phase (between 08:00 and 13:00 hours) for 1 week. The breakpoint or alternatively the highest completed ratio
(Olarte-Sa´nchez et al., 2012) was defined as the last ratio completed before 5 minutes elapsed without any responding.
Immunohistochemistry (IHC) and Fluorescent In Situ Hybridization Histochemistry (FISH)
IHC. Tissue was processed for GFP, mCherry, dsRed and/or c-Fos (FOS-IR) IHC as previously described (D’Agostino et al., 2016).
Briefly, mice were transcardially perfused with phosphate buffered saline (PBS) followed by 10% neutral buffered formalin (Sigma-
Aldrich). Brains were extracted, post-fixed in 10% neutral buffered formalin at 4C, cryoprotected in 20% sucrose at 4C and then
sectioned coronally on a freezing sliding microtome at 25 mm. Tissue was processed for chicken anti-GFP (1:1000; AbCam,
ab13970), rabbit anti-dsRED (1:1000; Rockland, 600-401-379), goat anti-mCherry/RFP (1:1000; Sicgen, AB0040-200) or anti-c-
FOS (1:5000, rabbit, Calbiochem, PC38) primary antibodies and a biotinylated donkey anti-rabbit (1:500, Jackson ImmunoResearch
Laboratories, Inc.) or Alexa Fluor (1:500, Life Technologies) secondary antibodies using standard protocols previously described
(Lam et al., 2009; Heisler et al., 2006). Tissue was then mounted on slides, cover slipped and the NTS visualized using an
Axioskop II microscope (Carl Zeiss, Oberkochen, Germany) and Adobe Photoshop CS5 software. Images of single-label immuoreac-
tivity (IR) for GFP or mCherry were used to visualize and analyze NTS injection sites.
Dual-IHC
Dual-IHC was performed to visualize co-expression of mCherry-IR and FOS-IR in 5-HT2CR
NTS-hM3Dq mice. Specifically, mice were
fasted overnight and then injected with designer drug CNO or saline. Brains were extracted 90 minutes later and dual-label mCherry
and FOS-IR performed using method outlined above. Quantitative analysis of single and dual-labelled cells was performed manually
using an Axioskop II microscope and Adobe Photoshop CS5 software.
IHC and FISH
IHC and FISH were performed to visualize co-expression of POMC and 5-HT2CR within the NTS in POMC
dsRED mice. To label
5-HT2CR expressing neurons, a RNA expression vector (pBluescript SK-) containing the 3-kilobase (kb) coding region of 5-HT2CR
cDNA was used to generate single-stranded RNA probes (Julius et al., 1988). Briefly, in vitro transcription was performed using
Digoxigenin (DIG)-RNA Labelling Mix (Roche, Mannheim, Germany). Sections were treated with 1% Sodium Borohydride solution
and 0.25% Acetic Anhydride in Triethanolamine (TEA) solution. Sections were then incubated in a hybridization buffer containing
a DIG-UTP-labelled 5-HT2CR riboprobe overnight at 55
C. Sections were rinsed in a standard sodium citrate/50% formamide solu-
tion, rinsed in an RNase (0.02 mg/ml RNase A) solution, incubated in a 3% H2O2 solution for 30 minutes and blocked in a 2% sheep
serum (Sigma-Aldrich, Saint Louis, MO USA). Sections were then incubated with an anti-DIG antibody (1:5000, Roche, Mannheim,
Germany), treated with TSA PLUS Biotin Kit (PerkinElmer Inc., Waltham, MA USA) and revealed with streptavidin conjugated Alexa
Fluor 568 (1:2000, Life Technologies, Carlsbad, CA USA). To label POMC, sections were blocked again and incubated with rabbit
anti-dsRED (1:1000; Rockland, Limerick, PA USA; 600-401-379) overnight at 4C using the IHC protocol described above. The sec-
tions were incubated with Alexa Fluor 568 donkey anti-rabbit secondary antibody (1:500, InvitrogenTM Life Technologies, Carlsbad,
CA USA) for 1 hour. Tissue was then mounted on slides, cover slipped and single- and dual-labelling assessed in the NTS using
an Axioskop II microscope and Adobe Photoshop CS5 software. Quantitative analysis of single and dual-labelled dsRed-IR and
5-HT2CR mRNA cells was conducted manually.
Enzyme Immunoassay (EIA) for Alpha-Melanocyte-Stimulating Hormone (Alpha-MSH)
Mice were anesthetized with sodium pentobarbital (Euthatal) and decapitated. The brain was rapidly removed, the hypothalamus
was dissected using razor blades and mouse acrylic brain matrices (Stoelting Co.) and frozen in dry ice. Hypothalamic lysates
were obtained using a probe sonicator. Lysis consisted of an acid-ethanol solution obtained by combining 1 part of concentrated
HCl with 7 parts pure ethanol. 0.1ml of lysis was used per 10 mg of tissue (weight of each hypothalamic explant was about
30 mg). 10 ml of crude homogenate were combined with 50 ml of fresh lysis buffer and centrifuged 3500 g for 30 min. Supernatants
were collected and dried using a vacuum centrifuge in low protein binding tubes (Eppendorf LoBind, Sigma-Aldrich, Cat No.
Z666505). Dry fractions were solubilised in 150 ml of assay buffer and alpha-MSH content analysed using a fluorescent EIA ultra-sen-
sitive assay (Phoenix Pharmaceutical Inc.; Cat No FEK-043-01) following the manufacturer’s instructions.
Electrophysiology and Chemogenetic Validation Analysis
For electrophysiological experiments, male and female POMCDS-Red (n=44), male loxtb5-HT2CR (n=9), male 5-HT2CR
NTS-hM3Dq
(n=2) or male 5-HT2CR
NTS-hM4Di (n=2) mice aged 2-6 months were anesthetized with sodium pentobarbital (Euthatal) and decapi-
tated. The brain was rapidly removed and placed in cold (0–4C), oxygenated (95%O2/5%CO2) ‘slicing’ solution containing (in mM)
sucrose (214), KCl (2.5), NaH2PO4 (1.2), NaHCO3 (26), MgSO4 (4), CaCl2 (0.1), D-glucose (10). The brain was fixed to a vibratingmicro-
tome (Campden Instruments, Loughborough, UK) and 200-mm thick coronal sections of the brainstem containing the NTS were pre-
pared. Slices were immediately transferred to a ‘recording’ solution containing (in mM) NaCl (127), KCl (2.5), NaH2PO4 (1.2), NaHCO3
(26), MgCl2 (1.3), CaCl2 (2.4) and D-glucose (10) in a continuously oxygenated holding chamber at 35
C for a period of 25 minutes.
Slices were remained in the recording solution at room temperature for a minimum of 1 hour before recording. For whole-cell record-
ings, slices were transferred to a submerged chamber and a Slicescope upright microscope (Scientifica, Uckfield, UK) was used for
infrared - differential interference contrast and fluorescence visualization of cells. During recording, slices were continuously
perfused at a rate of ca. 2 ml/minute with oxygenated recording solution at room temperature. All pharmacological compounds
were bath applied. Whole cell current-clamp recordings were performed with pipettes (3–7 MUwhen filled with intracellular solution)e4 Cell Metabolism 28, 619–630.e1–e5, October 2, 2018
made from borosilicate glass capillaries (World Precision Instruments, Aston, UK) pulled on a Zeitz DMZ micropipette puller (Zeitz
InstrumentsGmBH,Martinsried, Germany). The intracellular recording solution contained (inmM) K-gluconate (140), KCl (10), HEPES
(10), EGTA (1), Na2ATP (2), pH 7.3 (with KOH). Recordings were performed using aMulticlamp 700B amplifier and pClamp10 software
(Molecular Devices, Sunnyvale, CA USA). Liquid junction potential was 16.4 mV and not compensated. The recorded current was
sampled at 10 kHz and filtered at 2 kHz unless otherwise stated.
Drugs
Lorcaserin (LGM Pharma, Erlanger KY USA), WAY161,503 (Tocris Bioscience, Abingdon UK) and clozapine-n-oxide (CNO; Tocris
Bioscience) were prepared in double distilled H2O, diluted in sterile phosphate-buffered saline (PBS) and administered in vivo i.p.
in a volume of 10 ml/kg. 5-HT (Sigma-Aldrich), lorcaserin, WAY161,503 and CNO were dissolved in artificial cerebrospinal fluid
(aCSF) for electrophysiology experiments.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were analyzed with t-test, Mann Whitney U test, One-way, Two-way or Repeated Measures ANOVA followed by Tukey’s or
Sidak’s post hoc tests, where appropriate. For all analyses, significance was assigned at p<0.05. Data are presented asmean±SEM.
All statistical analyses were completed with GraphPad Prism 7.0 (GraphPad Software, San Diego, CA USA).Cell Metabolism 28, 619–630.e1–e5, October 2, 2018 e5
